USFDA clears manufacturing plants of India's leading drug companies in 10 days
Washington/Mumbai/IBNS: The US Food and Drug Administration (USFDA) has cleared the manufacturing plants of India's leading drug companies in 10 days, media reports said.
The decision came amid the shortages of supply of drugs across the world.
Lupin, which is the third largest generic drug supplier in the US by prescriptions, along with Dr. Reddy's Laboratories received reports indicating all investigations by the US drug regulator was closed.
Lupin managing director Nilesh Gupta said as quoted by Economic Times, “We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility."
All these came days after India decided to export anti-malaria drug and a "potent" COVID-19 cure, Hydroxychloroquine, to the US following a "retaliation" threat by Washington.
Though India is treating a number of Coronavirus patients with Hydroxychlorquine, the treatment has found no scientific backing as of yet.